Oncodesign Société Anonyme operates as a biopharmaceutical company focused on precision medicine for the discovery and development of therapies and diagnostic solutions for advanced and resistant cancers. The company provides drug discovery services and develops therapeutic and diagnostic solutions using proprietary technologies such as Nanocyclix for macrocyclization of small molecules and the OncoSniper program, which applies artificial intelligence to oncology drug discovery. It offers integrated drug discovery services, including target identification, medicinal chemistry, pharmacology, metabolism, pharmacokinetics, bioanalysis, and biobank management. The company conducts research collaborations for new drug candidates in oncology, rare diseases, and fibrosis, and has developed experimental cancer models and radiotracers such as Florepizol for non-small cell lung cancer. It also participates in biomarker programs and manages clinical studies for diagnostic and therapeutic compounds. The company serves biotechnology and pharmaceutical companies, as well as hospitals. The company was founded in 1995 and is based in Dijon, France.